178 related articles for article (PubMed ID: 15470906)
1. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance?
Boyle PJ
Clin Cardiol; 2004 Jul; 27(7 Suppl 4):IV11-6. PubMed ID: 15470906
[TBL] [Abstract][Full Text] [Related]
2. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
4. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama Y; Murase K; Ikeda H
Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
[TBL] [Abstract][Full Text] [Related]
5. [Effect of pioglitazone, one of TZDs, on IGT-patients].
Kobayashi M
Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
[No Abstract] [Full Text] [Related]
6. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Yang WS; Jeng CY; Wu TJ; Tanaka S; Funahashi T; Matsuzawa Y; Wang JP; Chen CL; Tai TY; Chuang LM
Diabetes Care; 2002 Feb; 25(2):376-80. PubMed ID: 11815513
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists.
Yue TL
Drugs Today (Barc); 2003 Dec; 39(12):949-60. PubMed ID: 14747840
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
Iwata M; Haruta T; Usui I; Takata Y; Takano A; Uno T; Kawahara J; Ueno E; Sasaoka T; Ishibashi O; Kobayashi M
Diabetes; 2001 May; 50(5):1083-92. PubMed ID: 11334412
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S
Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065
[TBL] [Abstract][Full Text] [Related]
12. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
13. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
Toyota T
Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Li AC; Brown KK; Silvestre MJ; Willson TM; Palinski W; Glass CK
J Clin Invest; 2000 Aug; 106(4):523-31. PubMed ID: 10953027
[TBL] [Abstract][Full Text] [Related]
16. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease.
Hsueh WA; Law R
Am J Cardiol; 2003 Aug; 92(4A):3J-9J. PubMed ID: 12957321
[TBL] [Abstract][Full Text] [Related]
17. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
18. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Sidhu JS; Cowan D; Kaski JC
J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
[TBL] [Abstract][Full Text] [Related]
19. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones.
Smith SA
Biochimie; 2003 Dec; 85(12):1219-30. PubMed ID: 14739074
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?
Pershadsingh HA
Expert Opin Investig Drugs; 2004 Mar; 13(3):215-28. PubMed ID: 15013941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
